SEC Filings TLDR

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process 8-K, 6-K, Schedule 13G. We will support more forms in the future.

2025-10-28TLSASCHEDULE 13GLaura Natalia Monica Fonda's Schedule 13G Filing for Tiziana Life Sciences LtdLOW
Laura Natalia Monica Fonda has filed a Schedule 13G with the SEC, disclosing her beneficial ownership of 6,805,556 shares of Tiziana Life Sciences Ltd, representing 5.70% of the company's common stock. The filing indicates that she has sole voting and dispositive power over these shares. The filing was made under Rule ...
2025-10-28NNNSCHEDULE 13GVictory Capital Management Inc's Schedule 13G Filing for NNN REIT, Inc.LOW
Victory Capital Management Inc filed a Schedule 13G with the SEC on October 28, 2025, disclosing its ownership of 9,754,456 shares of NNN REIT, Inc., representing 5.17% of the company's common stock. The filing indicates that Victory Capital Management Inc has sole voting power over 9,568,756 shares and sole dispositiv...
2025-10-28NITOSCHEDULE 13GSchedule 13G Filing by Dr. Alon Silberman for N2OFF, Inc.MEDIUM
Dr. Alon Silberman, a citizen of Israel and the Chief Executive Officer of MitoCareX Bio Ltd., a wholly owned subsidiary of N2OFF, Inc., has filed a Schedule 13G with the SEC. The filing discloses that Dr. Silberman beneficially owns 454,127 shares of common stock in N2OFF, Inc., representing 16.93% of the total outsta...
2025-10-28IVFSCHEDULE 13GGreenBlock Capital, LLC and Christopher Spencer Schedule 13G Filing for INVO Fertility, Inc.MEDIUM
GreenBlock Capital, LLC and Christopher Spencer have filed a Schedule 13G with the SEC regarding their ownership of common stock in INVO Fertility, Inc. GreenBlock Capital, LLC, a Florida-based limited liability company, and Christopher Spencer, the manager of GreenBlock, jointly report beneficial ownership of 617,954 ...
2025-10-28NDRASCHEDULE 13GATW Master Fund V LP and Others File Schedule 13G for ENDRA Life Sciences Inc.MEDIUM
ATW Master Fund V LP, ATW Partners Opportunities Management, LLC, Kerry Propper, and Antonio Ruiz-Gimenez have filed a Schedule 13G for ENDRA Life Sciences Inc. The filing indicates that ATW Master Fund V LP holds 116,024 shares of common stock, representing 9.9% of the outstanding shares. The shares are subject to a b...
2025-10-28DOLESCHEDULE 13GVictory Capital Management Inc Increases Stake in Dole plcMEDIUM
Victory Capital Management Inc has filed a Schedule 13G with the SEC, disclosing an increased stake in Dole plc. As of September 30, 2025, Victory Capital Management Inc owns 4,938,971 shares of Dole plc's common stock, representing a 5.19% ownership. This marks an increase of 1,155,983 shares, or 30.56%, from their pr...
2025-10-28CLCOSCHEDULE 13GJNE Partners LLP Acquires 5.12% Stake in Cool Co Ltd.MEDIUM
JNE Partners LLP, along with JNE Master Fund LP and Jonathan Esfandi, has acquired a 5.12% stake in Cool Co Ltd., as reported in a Schedule 13G filing with the SEC. The filing indicates that the group beneficially owns 2,708,686 shares of common stock, representing 5.12% of the outstanding shares. The shares are held f...
2025-10-28CHRDSCHEDULE 13GVictory Capital Management Inc's 13G Filing for Chord Energy CorpMEDIUM
Victory Capital Management Inc filed a Schedule 13G with the SEC, disclosing its ownership of 2,983,086 shares of Chord Energy Corp's common stock, representing 5.47% of the total shares outstanding. The filing indicates that Victory Capital Management has sole voting power over 2,882,626 shares and sole dispositive po...
2025-10-28CMASCHEDULE 13GBank of New York Mellon Corp Acquires 5.7% Stake in Comerica IncMEDIUM
The Bank of New York Mellon Corporation has filed a Schedule 13G indicating it has acquired a 5.7% stake in Comerica Inc. The filing, dated October 28, 2025, shows that the bank and its subsidiaries beneficially own 7,291,514 shares of Comerica's common stock. The shares are held in various fiduciary capacities, and no...
2025-10-28CISSSCHEDULE 13GAthanasios Tsiakmakis Reports 14.36% Ownership in C3is Inc.MEDIUM
Athanasios Tsiakmakis has filed a Schedule 13G with the SEC, reporting ownership of 14.36% of the common stock of C3is Inc. as of October 27, 2025. The filing indicates that Tsiakmakis beneficially owns 155,000 shares, with sole voting and dispositive power over these shares. The filing is made pursuant to Rule 13d-1(c...
2025-10-28BKSCHEDULE 13GBank of New York Mellon Corp Files Schedule 13G for Comerica IncMEDIUM
The Bank of New York Mellon Corporation has filed a Schedule 13G with the SEC, disclosing its ownership of 7,291,514 shares of Comerica Inc's common stock, representing a 5.7% ownership stake. The filing indicates that these shares are held in various fiduciary capacities by The Bank of New York Mellon Corporation and ...
2025-10-28AOMNSCHEDULE 13GVictory Capital Management, Inc. Reports 6.06% Ownership in Angel Oak Mortgage REIT, Inc.MEDIUM
Victory Capital Management, Inc. has filed a Schedule 13G with the SEC, reporting a 6.06% ownership stake in Angel Oak Mortgage REIT, Inc. The filing indicates that Victory Capital Management, Inc. beneficially owns 1,440,411 shares of common stock in Angel Oak Mortgage REIT, Inc. The shares are held solely by Victory ...
2025-10-27IPWSCHEDULE 13GWhite Cherry Limited and Xinbo Du's Ownership in iPower Inc.MEDIUM
White Cherry Limited and Xinbo Du have filed a Schedule 13G indicating their ownership in iPower Inc. White Cherry Limited, a British Virgin Islands company, and Xinbo Du, its sole member, collectively own 3,083,700 shares of iPower Inc.'s common stock, representing 9.8% of the total shares. The filing certifies that t...
2025-10-27XRTXSCHEDULE 13GLincoln Alternative Strategies LLC Reports 9.9% Ownership in XORTX Therapeutics Inc.MEDIUM
Lincoln Alternative Strategies LLC has filed a Schedule 13G with the SEC, reporting beneficial ownership of 572,470 common shares of XORTX Therapeutics Inc., representing 9.9% of the outstanding shares. The filing indicates that the shares were not acquired for the purpose of influencing the control of the issuer. Linc...
2025-10-27IPWSCHEDULE 13GiPower Inc. Schedule 13G Filing by White Cherry Limited and Xinbo DuLOW
The filing discloses that White Cherry Limited, a British Virgin Islands company, and Xinbo Du, its sole member, collectively own 9.8% of the common stock of iPower Inc. This amounts to 3,083,700 shares. The filing is made under Rule 13d-1(c) of the Securities Exchange Act of 1934. The reporting persons certify that th...
2025-10-27TRINZSCHEDULE 13GTrinity Capital Inc. Reports 17% Ownership in Eagle Point Trinity Senior Secured Lending CompanyMEDIUM
Trinity Capital Inc. has filed a Schedule 13G with the SEC, disclosing a 17% ownership stake in Eagle Point Trinity Senior Secured Lending Company. Trinity Capital Inc. holds 1,002,204 common shares of beneficial interest, with sole voting and dispositive power over these shares. The filing indicates that Trinity Capit...
2025-10-27NXDRSCHEDULE 13GSumitomo Mitsui Trust Group and Amova Asset Management Report 5.7% Stake in Nextdoor HoldingsMEDIUM
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G reporting a 5.7% ownership in Nextdoor Holdings, Inc. The filing indicates that both entities share voting and dispositive power over 13,660,830 shares of Class A common stock. The securities are held through their subsidia...
2025-10-27IBTASCHEDULE 13GSumitomo Mitsui Trust Group and Amova Asset Management Report 5.1% Ownership in Ibotta, Inc.MEDIUM
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G indicating a 5.1% beneficial ownership in Ibotta, Inc.'s Class A Common Stock. The filing details that Sumitomo Mitsui Trust Group holds 1,279,895 shares, while Amova Asset Management holds 1,279,655 shares. Both entities a...
2025-10-27LXEOSCHEDULE 13GRA Capital Management, L.P. and Affiliates File Schedule 13G for Lexeo Therapeutics, Inc.MEDIUM
RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G with the SEC on October 27, 2025, disclosing their beneficial ownership of 5,000,000 shares of Lexeo Therapeutics, Inc.'s common stock, representing 6.9% of the outstanding shares. The filin...
2025-10-27QNRXSCHEDULE 13GSchedule 13G Filing by Integrated Core Strategies (US) LLC and Others for Quoin Pharmaceuticals Ltd.MEDIUM
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G with the SEC, disclosing their beneficial ownership of Ordinary Shares in Quoin Pharmaceuticals Ltd. The filing indicates that these entities collectively own approx...
2025-10-27NXDRSCHEDULE 13GSumitomo Mitsui Trust Group and Amova Asset Management Report 5.7% Ownership in Nextdoor HoldingsMEDIUM
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G reporting a 5.7% ownership stake in Nextdoor Holdings, Inc. The filing indicates that the two entities collectively own 13,660,830 shares of Class A common stock. Both companies are classified as parent holding companies an...
2025-10-27XRTXSCHEDULE 13GLincoln Alternative Strategies LLC Reports 9.9% Ownership in XORTX Therapeutics Inc.LOW
Lincoln Alternative Strategies LLC has filed a Schedule 13G indicating ownership of 572,470 common shares of XORTX Therapeutics Inc., representing 9.9% of the total outstanding shares. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of influencing the control of the iss...
2025-10-27LXEOSCHEDULE 13GRA Capital Management, L.P. Files Schedule 13G for Lexeo Therapeutics, Inc.MEDIUM
RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G with the SEC on October 27, 2025, disclosing beneficial ownership of 5,000,000 shares of common stock in Lexeo Therapeutics, Inc. This represents 6.9% of the company's outstanding shares. Th...
2025-10-27KROSSCHEDULE 13GD. E. Shaw & Co. Reports 5.1% Ownership in Keros Therapeutics, Inc.MEDIUM
D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., and David E. Shaw have filed a Schedule 13G with the SEC, reporting a 5.1% ownership in Keros Therapeutics, Inc. The filing details the beneficial ownership of 1,545,948 shares of common stock, which includes shares managed by D. E. Shaw Valence Portfolios, L.L.C., D. E...
2025-10-27IBTASCHEDULE 13GSumitomo Mitsui Trust Group and Amova Asset Management Co. Report 5.1% Ownership in Ibotta, Inc.MEDIUM
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed a Schedule 13G reporting a 5.1% ownership in Ibotta, Inc. The filing indicates that both entities collectively own 1,279,895 shares of Class A Common Stock. Sumitomo Mitsui Trust Group, Inc. is classified as a parent holding company, whil...
Previous Page123456Next Page